<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36880687</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-185X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>9</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>International journal of rheumatic diseases</Title><ISOAbbreviation>Int J Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>Systemic lupus erythematosus flare during SARS-CoV-2 infection: Report of 3 cases presented during the fourth wave of the pandemic in Colombia.</ArticleTitle><Pagination><StartPage>1807</StartPage><EndPage>1810</EndPage><MedlinePgn>1807-1810</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/1756-185X.14657</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has become a worldwide pandemic since first discovered in 2019. Systemic lupus erythematosus (SLE) flare has been reported in the post-infectious period. In Colombia, the fourth pandemic wave started at the beginning of 2022 when we observed flare of 3 SLE patients during active infection.</AbstractText><AbstractText Label="CASE PRESENTATION" NlmCategory="METHODS">We describe 3 patients with inactive SLE, who presented coronavirus disease 2019 and severe flare in early 2022, 2 patients with nephritis and 1 with severe thrombocytopenia. All patients had increase of antinuclear and anti-DNA antibody titers and complement consumption.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Three cases with SLE flare concomitant with active SARS-CoV-2 infection were different from others reported earlier in the pandemic with post-infectious flare.</AbstractText><CopyrightInformation>&#xa9; 2023 Asia Pacific League of Associations for Rheumatology and John Wiley &amp; Sons Australia, Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Naranjo-Mill&#xe1;n</LastName><ForeName>Juli&#xe1;n Alberto</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Ciencias de la Salud, Universidad Icesi, Unidad de Reumatolog&#xed;a, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedoya-Joaqui</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Ciencias de la Salud, Universidad Icesi, Unidad de Reumatolog&#xed;a, Cali, Colombia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ca&#xf1;as</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-6879-3700</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Facultad de Ciencias de la Salud, Universidad Icesi, Unidad de Reumatolog&#xed;a, Cali, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3;n Valle del Lili, Unidad de Reumatolog&#xed;a, Cali, Colombia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centro de Investigaci&#xf3;n en Reumatolog&#xed;a, Autoinmunidad y Medicina Traslacional (CIRAT), Universidad Icesi, Cali, Colombia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Int J Rheum Dis</MedlineTA><NlmUniqueID>101474930</NlmUniqueID><ISSNLinking>1756-1841</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003105" MajorTopicYN="N" Type="Geographic">Colombia</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">lupus nephritis</Keyword><Keyword MajorTopicYN="N">thrombocytopenia</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>1</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>5</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>7</Day><Hour>8</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36880687</ArticleId><ArticleId IdType="doi">10.1111/1756-185X.14657</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Mistry P, Barmania F, Mellet J, et al. SARS-CoV-2 variants, vaccines, and host immunity. Front Immunol. 2022;12:12. doi:10.3389/fimmu.2021.809244</Citation></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, et al. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell. 2020;183:158-68.e14. doi:10.1016/j.cell.2020.08.017</Citation></Reference><Reference><Citation>Mehta P, Fajgenbaum DC, Puja Mehta DCF. Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. Curr Opin Rheumatol. 2021;33:419-430. doi:10.1097/BOR.0000000000000822</Citation></Reference><Reference><Citation>Mantovani Cardoso E, Hundal J, Feterman D, Magaldi J. Concomitant new diagnosis of systemic lupus erythematosus and COVID-19 with possible antiphospholipid syndrome. Just a coincidence? A case report and review of intertwining pathophysiology. Clin Rheumatol. 2020;39:2811-2815. doi:10.1007/s10067-020-05310-1</Citation></Reference><Reference><Citation>Schioppo T, Argolini LM, Sciascia S, et al. Clinical and peculiar immunological manifestations of SARS-CoV-2 infection in systemic lupus erythematosus patients. Rheumatology. 2021;61:1928-1935. doi:10.1093/rheumatology/keab611</Citation></Reference><Reference><Citation>Kichloo A, Aljadah M, Albosta M, Wani F, Singh J, Solanki S. COVID-19 and acute lupus pneumonitis: diagnostic and treatment dilemma. J Investig Med High Impact Case Rep. 2020;8:232470962093343. doi:10.1177/2324709620933438</Citation></Reference><Reference><Citation>Aram K, Patil A, Goldust M, Rajabi F. COVID-19 and exacerbation of dermatological diseases: a review of the available literature. Dermatol Ther. 2021;34:e15113. doi:10.1111/dth.15113</Citation></Reference><Reference><Citation>Raghavan S, Gonakoti S, Asemota IR, Benjamin M. A case of systemic lupus erythematosus flare triggered by severe coronavirus disease 2019. Journal of Clinical Rheumatology. 2020;26:234-235. doi:10.1097/RHU.0000000000001531</Citation></Reference><Reference><Citation>Khalid MZ, Rogers S, Fatima A, Dawe M, Singh R. A flare of systemic lupus erythematosus disease after COVID-19 infection: a case of lupus cerebritis. Cureus. 2021;13:e16104. doi:10.7759/cureus.16104</Citation></Reference><Reference><Citation>Keshavarz F, Ghalamfarsa F, Javdansirat S, et al. Patients with COVID 19 have significantly reduced CH50 activity. Virusdisease. 2021;32:681-689. doi:10.1007/s13337-021-00710-6</Citation></Reference><Reference><Citation>Nasser N, Kurban M, Abbas O. Plasmacytoid dendritic cells and type I interferons in flares of systemic lupus erythematosus triggered by COVID-19. Rheumatol Int. 2021;41:1019-1020. doi:10.1007/s00296-021-04825-3</Citation></Reference><Reference><Citation>Ca&#xf1;as CA. The triggering of post-COVID-19 autoimmunity phenomena could be associated with both transient immunosuppression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020;145:110345. doi:10.1016/j.mehy.2020.110345</Citation></Reference><Reference><Citation>Zuo Y, Yalavarthi S, Shi H, et al. Neutrophil extracellular traps in COVID-19. JCI Insight. 2020;5:138999. doi:10.1172/jci.insight.138999</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>